WELL Health vs. Docebo: Better Tech Stock to Buy Right Now?

Let’s look at the recent performances and growth prospects of Well Health and Docebo to identify a better buy.

| More on:

Canadian equity markets have rebounded strongly over the last few weeks amid easing recession fears, with the S&P/TSX Composite Index rising 9.9% higher this year. Amid improving investors’ optimism, let’s assess which of WELL Health Technologies (TSX:WELL) and Docebo (TSX:DCBO) would be a better tech stock to buy now based on their recent quarterly performances and growth prospects.

WELL Health Technologies

Earlier this month, WELL Health reported an impressive second-quarter performance, with its top line growing by 42% to $243.1 million. An organic growth of 21% and acquisitions over the last four quarters drove its sales. It witnessed solid performances across its three segments. During the quarter, it had 1.4 million patient visits and 2.1 million patient interactions, representing a year-over-year growth of 38% and 48%, respectively.

Amid the top-line growth, its adjusted gross profits increased by 18% to $107.4 million. However, its gross profit margin declined from 53.1% to 44.2% amid the acquisition of lower-margin businesses. Further, its adjusted EBITDA (earnings before interest, tax, depreciation, and amortization) increased by 11%, while adjusted EBITDA to WELL shareholders grew by 3%. It also generated $35.2 million of cash from its operations, thus helping it to pay off $14 million of debt, lowering its leverage ratio to 2.67.

Meanwhile, I expect the uptrend in WELL Health’s financials to continue amid its expanding addressable market and growth initiatives. The increased usage of virtual services, digitization of patient records, and adoption of software solutions in the healthcare segment have expanded its addressable market. The company is implementing advanced artificial intelligence tools, patient engagement technologies, and digital workflow integration, which could grow its market share and drive its financials in the coming years. It has also adopted several cost-cutting initiatives, which could improve its profitability.

Docebo

Docebo also reported an impressive second-quarter performance earlier this month, beating its guidance. Its topline grew by 22% to $53.1 million. The addition of 307 customers over the last four quarters and an increase of 9.7% in its average contract value drove its financials. Supported by its top-line growth, its adjusted EPS (earnings per share) grew by 85.7% to $0.26. The company also generated free cash flows of $8.45 million during the quarter, representing a 20% year-over-year increase.

The usage of digital learning tools in academics and businesses is growing, thus expanding Docebo’s addressable market. Meanwhile, the company is introducing artificial intelligence-powered features to enhance its customers’ experience. The company has signed long-term agreements with its customers, providing financial stability. Amid its solid second-quarter performance and growth initiatives, the company’s management expects its 2024 top line to grow 18-19% while its adjusted EBITDA margin could be around 15-15.5%.

Investors’ takeaway

Supported by its solid performances, WELL Health is up 19.2% this year, outperforming the broader equity markets. Despite its strong returns, the company trades at an attractive valuation, with its next-12-month price-to-earnings multiple at 16.8.

Meanwhile, Docebo has underperformed the broader equity markets this year, with its stock price losing 9.1%. Despite the decline in stock price, the company’s valuation looks expensive, with its NTM price-to-earnings multiple standing at 38.2. Although both companies offer high growth prospects, I am more bullish on WELL Health due to its cheaper valuation.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Rajiv Nanjapla has no position in any of the stocks mentioned. The Motley Fool recommends Docebo. The Motley Fool has a disclosure policy.

More on Investing

think thought consider
Investing

Should You Buy Couche-Tard Stock Aggressively Before Nov. 25?

Here’s what could help Couche-Tard stock rebound after its upcoming earnings event.

Read more »

calculate and analyze stock
Bank Stocks

4% Dividend Yield? I Keep Buying This Dividend Stock in Bulk!

If you find the perfect dividend stock, you never have to worry about investing again. And that's what you get…

Read more »

Paper Canadian currency of various denominations
Dividend Stocks

Should You Buy the 3 Highest-Paying Dividend Stocks in Canada?

A few dividend stocks saw a sharp correction in November, increasing their yields. Are they a buy for high dividends?

Read more »

oil and natural gas
Investing

Is Imperial Oil Stock a Buy for its 2.3% Dividend Yield?

Imperial Oil (TSX:IMO) stock: A century of dividends, 30 years of growth, and a 2.3% yield that could evolve into…

Read more »

Paper Canadian currency of various denominations
Stock Market

3 No-Brainer Stocks to Buy Right Now for Less Than $120

Here are three undervalued TSX stocks that are positioned to deliver outsized gains to shareholders over the next 12 months.

Read more »

Man holds Canadian dollars in differing amounts
Investing

Have $500? 3 Absurdly Cheap Stocks Long-term Investors Should Buy Right Now

These three cheap stocks offer excellent buying opportunities for long-term investors.

Read more »

money while you sleep
Dividend Stocks

Buy These 2 High-Yield Dividend Stocks Today and Sleep Soundly for a Decade

These stocks pay attractive dividends that should continue to grow.

Read more »

Pile of Canadian dollar bills in various denominations
Dividend Stocks

$15,000 Windfall? This Dividend Stock Is the Perfect Buy for Monthly Passive Income

If you get a windfall, after debt investing should be your next top option to create even more passive income!

Read more »